SCHEMBL6726593

SCHEMBL6726593

CN(C(=O)C(NC(=O)O)c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.41
KLRK1 P26718 1/20 0.41
MICA Q29983 1/20 0.41
RAET1L Q5VY80 1/20 0.41
UTS2R Q9UKP6 7/20 0.40
S1PR4 O95977 1/20 0.40
S1PR3 Q99500 1/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
ACLY P53396 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3506072 0.78 TACR3 (0.51) KMT2AKLRK1MICARAET1LLMNA
SCHEMBL14831389 0.75 PKM (0.48) L3MBTL1RAB9AKLRK1MICARAET1L
SCHEMBL16830012 0.73 OPRK1 (0.44) MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6825332 0.72 SIGMAR1 (0.49) SLC6A2SLC6A4KDM4EALDH1A1
SCHEMBL6715725 0.72 MEN1 (0.54) MEN1KMT2AS1PR4S1PR3KDM4E
SCHEMBL28394955 0.72 CHRNB2 (0.44) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL17664138 0.71 ALDH1A1 (0.56) NPC1RAB9AS1PR4S1PR3LMNA
SCHEMBL6716797 0.71 HDAC1 (0.39) HDAC1SLC6A2SLC6A4L3MBTL1NPC1
SCHEMBL24339824 0.71 MLYCD (0.56) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL4205971 0.71 HPGD (0.55) NPC1RAB9AMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 HDAC1 2586/4885SLC6A2 22/4885SLC6A4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.